BiotechTube
Home/Werewolf Therapeutics/Randall C. Schatzman, Ph.D.
RC

Randall C. Schatzman, Ph.D.

Chief Business Officer

Werewolf Therapeutics

Therapeutic Areas

Oncology

Werewolf Therapeutics Pipeline

DrugIndicationPhase
WTX-124Advanced or metastatic solid tumorsPhase 1
WTX-330Advanced or metastatic solid tumors / non-Hodgkin lymphomaPhase 1
WTX-518UndisclosedPreclinical
WTX-712UndisclosedPreclinical

Leadership Team at Werewolf Therapeutics

DJ
Daniel J. Hicklin, Ph.D.
President, Chief Executive Officer, and Co-Founder
JO
James O. B. McCarthy, Jr.
Chief Financial Officer
CS
Cynthia Seidel-Dugan, Ph.D.
Chief Scientific Officer
TP
Timothy P. Reilly, Ph.D.
Chief Operating Officer
CP
Chulho Park, Ph.D.
Senior Vice President, Translational Sciences
IM
Ian M. Smith, J.D.
General Counsel and Corporate Secretary
DE
Douglas E. Williams, Ph.D.
Chairman of the Board
EC
Ellen Chiniara, J.D.
Director
JL
John L. Ryan, Ph.D.
Director
LE
Luke Evnin, Ph.D.
Director
View full Werewolf Therapeutics profile